Evidence map›Paper›PMID 36364631›Full record

ReviewNanomaterials (Basel, Switzerland)2022

Recent Advances in the Development of Lipid-, Metal-, Carbon-, and Polymer-Based Nanomaterials for Antibacterial Applications.

Ruohua Ren, Chiaxin Lim, Shiqi Li, Yajun Wang, Jiangning Song, Tsung-Wu Lin, Benjamin W Muir, Hsien-Yi Hsu, Hsin-Hui Shen

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review of Antimicrobial Properties of Carbon Nanomaterials.International journal of molecular sciences · 2026
    Review
  8. Antibacterial Activity of Quantum-Confined One-Dimensional Titanate Nanofilaments.Langmuir : the ACS journal of surfaces and colloids · 2026
    Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ruohua RenDepartment of Materials Science and Engineering, Faculty of Engineering, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0001-7647-1878
Chiaxin LimDepartment of Materials Science and Engineering, Faculty of Engineering, Monash University, Clayton, VIC 3800, Australia.
Shiqi LiDepartment of Materials Science and Engineering, Faculty of Engineering, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0002-9619-9688
Yajun WangCollege of Chemistry & Materials Engineering, Wenzhou University, Wenzhou 325035, China.ORCID 0000-0002-7557-5883
Jiangning SongBiomedicine Discovery Institute, Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.ORCID 0000-0001-8031-9086
Tsung-Wu LinDepartment of Chemistry, Tunghai University, No.1727, Sec.4, Taiwan Boulevard, Xitun District, Taichung 40704, Taiwan.
Benjamin W MuirCSIRO, Manufacturing, Clayton, VIC 3169, Australia.
Hsien-Yi HsuSchool of Energy and Environment, Department of Materials Science and Engineering, City University of Hong Kong, Kowloon Tong, Hong Kong 518057, China.ORCID 0000-0001-5931-271X
Hsin-Hui ShenDepartment of Materials Science and Engineering, Faculty of Engineering, Monash University, Clayton, VIC 3800, Australia.

Funding

National Health and Medical Research Council GNT1106798
6 · The paper itself

Abstract

Infections caused by multidrug-resistant (MDR) bacteria are becoming a serious threat to public health worldwide. With an ever-reducing pipeline of last-resort drugs further complicating the current dire situation arising due to antibiotic resistance, there has never been a greater urgency to attempt to discover potential new antibiotics. The use of nanotechnology, encompassing a broad range of organic and inorganic nanomaterials, offers promising solutions. Organic nanomaterials, including lipid-, polymer-, and carbon-based nanomaterials, have inherent antibacterial activity or can act as nanocarriers in delivering antibacterial agents. Nanocarriers, owing to the protection and enhanced bioavailability of the encapsulated drugs, have the ability to enable an increased concentration of a drug to be delivered to an infected site and reduce the associated toxicity elsewhere. On the other hand, inorganic metal-based nanomaterials exhibit multivalent antibacterial mechanisms that combat MDR bacteria effectively and reduce the occurrence of bacterial resistance. These nanomaterials have great potential for the prevention and treatment of MDR bacterial infection. Recent advances in the field of nanotechnology are enabling researchers to utilize nanomaterial building blocks in intriguing ways to create multi-functional nanocomposite materials. These nanocomposite materials, formed by lipid-, polymer-, carbon-, and metal-based nanomaterial building blocks, have opened a new avenue for researchers due to the unprecedented physiochemical properties and enhanced antibacterial activities being observed when compared to their mono-constituent parts. This review covers the latest advances of nanotechnologies used in the design and development of nano- and nanocomposite materials to fight MDR bacteria with different purposes. Our aim is to discuss and summarize these recently established nanomaterials and the respective nanocomposites, their current application, and challenges for use in applications treating MDR bacteria. In addition, we discuss the prospects for antimicrobial nanomaterials and look forward to further develop these materials, emphasizing their potential for clinical translation.

Indexed as

antimicrobialdrug delivery systemsmultidrug-resistant bacteriananomaterialsnanoparticles

Identifiers

PMID36364631
PMCPMC9658259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.